Segluromet 2.5mg/850mg Film-Coated Tablets
Segluromet 2.5mg/1000mg Film-Coated Tablets
Segluromet 7.5mg/850mg Film-Coated Tablets
Segluromet 7.5mg/1000mg Film-Coated Tablets
ertugliflozina/metformina hidrocloruro
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
1.What is Segluromet and what it is used for
2.What you need to know before starting Segluromet
3.How to take Segluromet
4.Possible side effects
5.Storage of Segluromet
6.Contents of the pack and additional information
What is Segluromet
Segluromet contains two active ingredients, ertugliflozina and metformina. Each one belongs to a group of medications called "oral antidiabetic medications". These are medications taken by mouth to treat diabetes.
What is Segluromet used for
How Segluromet works
What is type 2 diabetes?
Type 2 diabetes is a disease in which the body does not produce enough insulin or the insulin produced by the body does not function as well as it should. This leads to high blood sugar levels. When this occurs, it can cause serious medical problems, such as heart disease, kidney disease, blindness, and poor circulation.
Do not take Segluromet
Do not take Segluromet if you are affected by any of the above situations. If you are unsure, consult your doctor before taking Segluromet.
Warnings and precautions
Risk of lactic acidosis
Segluromet may cause a rare but serious side effect called lactic acidosis, especially if your kidneys do not function properly. The risk of lactic acidosis also increases in cases of uncontrolled diabetes, severe infections, prolonged fasting or alcohol consumption, dehydration (see additional information below), liver problems, and any disease in which a part of the body receives insufficient oxygen (such as acute and severe heart disease).
If you are affected by any of the above situations, consult your doctor for further instructions.
Stop taking Seglurometfor a short period of time if you have a condition that may be associated with dehydration(significant loss of body fluids) such as intense vomiting, diarrhea, fever, exposure to heat or if you drink less fluid than normal. Consult your doctor for additional instructions.
Stop taking Segluromet and contact a doctor or go to the nearest hospital immediately if you experience any of the symptoms of lactic acidosis, as this condition can end in coma.
The symptoms of lactic acidosis include:
Consult your doctor, pharmacist, or nurse before starting to take and during treatment with Segluromet if you:
It is essential that you regularly inspect your feet and follow the advice given by your healthcare professional on foot care.
Consult your doctor immediately if you present a combination of symptoms of pain, tenderness, redness or inflammation of the genitals or the area between the genitals and the anus, with fever or general malaise. These symptoms may be a sign of a rare but potentially life-threatening infection, even potentially fatal, called necrotizing fasciitis of the perineum or Fournier's gangrene, which destroys tissue under the skin. Fournier's gangrene should be treated immediately.
When this medication is used in combination with insulin or medications that increase insulin release by the pancreas, hypoglycemia (low blood sugar) may occur. Your doctor may reduce the dose of your insulin or other medications.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
If you need to undergo major surgery, you should stop taking Segluromet during the procedure and for a certain period of time afterwards. Your doctor will decide when to interrupt and resume your treatment with Segluromet.
During treatment with Segluromet, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person or if your kidney function is worsening.
Blood glucose in urine
Due to the way Segluromet works, your urine will test positive for sugar (glucose) while you are taking this medication.
Children and adolescents
Children and adolescents under 18years should not take this medication. The safety and efficacy of this medication in children and adolescents under 18years have not been established.
Other medications and Segluromet
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medication.
You may need to have blood tests more frequently to check your blood glucose levels and kidney function or your doctor may need to adjust the dose of Segluromet. In particular, inform your doctor:
If you are affected by any of the above situations (or are unsure), inform your doctor.
If you need to receive an injection of a contrast medium containing iodine, for example, in the context of aradiography or scan, you should stop taking Segluromet before or at the time of the injection. Your doctor will decide when to interrupt and resume your treatment with Segluromet.
Segluromet and alcohol
Avoid excessive alcohol consumption while taking Segluromet, as this may increase the risk of lactic acidosis (see section “Warnings and precautions”).
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, consult your doctor or pharmacist before using this medication.
The safety of Segluromet in pregnancy has not been established. If you are pregnant, consult your doctor about the best way to control your blood sugar during pregnancy. Do not use Segluromet if you are pregnant.
The safety of Segluromet in breastfeeding has not been established. Consult your doctor about the best way to feed your baby if you are taking this medication. Do not use Segluromet if you are breastfeeding.
Driving and operating machinery
The influence of this medication on the ability to drive and operate machinery is negligible or insignificant. However, taking this medication in combination with insulin or medications that increase insulin release by the pancreas may cause excessive lowering of blood sugar (hypoglycemia), which may cause symptoms such as tremors, sweating or visual disturbances and may affect your ability to drive and operate machinery. Do not drive or operate tools or machinery if you feel dizzy while taking Segluromet.
Segluromet contains sodium
This medication contains less than 1mmol of sodium (23mg) per tablet; that is, it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
How much to take
How to take this medication
If you take more Segluromet than you should
If you take an excessive amount of Segluromet, consult a doctor or pharmacist immediately.
If you forget to take Segluromet
What to do if you forget to take a tablet depends on the time remaining until your next dose.
Do not take a double dose (two doses at the same time) to compensate for missed doses.
If you interrupt treatment with Segluromet
Do not stop taking this medication without consulting your doctor. If you stop taking the medication, your blood sugar levels may increase.
If you have any other questions about using this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Contact a doctor or go to the nearest hospital immediately if you experience any of the following serious side effects:
Lactic acidosis (very rare, may affect up to 1 in 10,000 people)
Segluromet may cause a very rare but serious side effect called lactic acidosis (see the "Warnings and precautions" section). If this happens, stop taking Segluromet and contact a doctor or go to the nearest hospital immediately, as lactic acidosis can lead to coma.
Diabetic ketoacidosis (rare, may affect up to 1 in 1,000 people)
The following are the signs of diabetic ketoacidosis (also see the "Warnings and precautions" section):
This can occur regardless of your blood glucose levels. Your doctor may decide to temporarily or permanently discontinue your treatment with Segluromet.
Fournier's gangrene or necrotizing fasciitis of the perineum (unknown frequency, cannot be estimated from available data)
A severe infection of the soft tissues of the genitals or the area between the genitals and the anus (see the "Warnings and precautions" section for symptoms).
If you notice any of the previously mentioned side effects, contact a doctor or go to the nearest hospital immediately.
Contact your doctor as soon as possible if you notice the following side effects:
Urinary tract infection (very common, may affect more than 1 in 10 people)
The signs of urinary tract infection are:
Although it is rare, if you have a fever or see blood in your urine, inform your doctor immediately.
Dehydration (excessive loss of water from the body; common, may affect up to 1 in 10 people)
The symptoms of dehydration include:
You are more likely to become dehydrated if you:
Low blood sugar (hypoglycemia; common)
Your doctor will instruct you on how to treat low blood sugar and what to do if you experience any of the following symptoms or signs. Your doctor may reduce your insulin dose or the dose of other diabetes medications.
The symptoms and signs of low blood sugar may include:
If you notice any of the previously mentioned side effects, contact your doctor as soon as possible.
Other side effects include:
Very common
Common
Rare (may affect up to 1 in 100 people)
Very rare
Unknown frequency
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through thenational notification systemincluded in theAppendixV. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the container after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Do not use this medication if you observe that the container is damaged or shows signs of manipulation.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. In this way, you will help protect the environment.
Composition of Segluromet
Film-coated tablets of Segluromet 2.5 mg/1,000 mg and film-coated tablets of Segluromet 7.5 mg/1,000 mg: hypromellose (E464), hydroxypropylcellulose (E463), titanium dioxide (E171), iron oxide red (E172), carnauba wax (E903).
Appearance of the product and contents of the package
Segluromet is available in Alu/PVC/PA/Alu blister packs. The package sizes are 14, 28, 56, 60, 168, 180, and 196 film-coated tablets in uncut blister packs and 30 film-coated tablets in pre-cut blister packs for single-dose use.
Only some package sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien MSD Belgium Tel/Tel: +32(0)27766211 dpoc_belux@msd.com | Lietuva UAB Merck Sharp & Dohme Tel: + 370 5 2780247 msd_lietuva@merck.com |
Luxembourg/Luxemburg MSD Belgium Tél/Tel:+32(0)27766211 dpoc_belux@msd.com | |
Ceská republika Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 111 dpoc_czechslovak@merck.com | Magyarország MSD Pharma Hungary Kft. Tel.: +36 1 888-5300 hungary_msd@merck.com |
Danmark MSD Danmark ApS Tlf.:+4544824000 dkmail@merck.com | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Deutschland MSD Sharp & Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 0) e-mail@msd.de | Nederland Merck Sharp & Dohme B.V. Tel:0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Eesti Merck Sharp & Dohme OÜ Tel: + 372 6144 200 msdeesti@merck.com | Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd.no |
Ελλ?δα MSD Α.Φ.Ε.Ε. Τηλ: +30 210 98 97 300 dpoc_greece@merck.com | Österreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com |
España Merck Sharp& Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@merck.com | Polska MSD Polska Sp. z o.o. Tel.: +48 22 549 51 00 msdpolska@merck.com |
France MSD France Tél: + 33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com |
Hrvatska Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 croatia_info@merck.com | România Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@msd.com | Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel:+38615204201 msd_slovenia@merck.com |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Merck Sharp & Dohme, s.r.o. Tel: +421 (2) 58282010 dpoc_czechslovak@merck.com |
Italia MSD Italia S.r.l. Tel:800 23 99 89 (+39 06 361911) dpoc.italy@msd.com | Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804650 info@msd.fi |
Κ?προς Merck Sharp & Dohme Cyprus Limited Τηλ: 800 00 673 +357 22866700 cyprus_info@merck.com | Sverige Merck Sharp & Dohme (Sweden) AB Tfn: +46 (0)77 570 04 88 medicinskinfo@merck.com |
Latvija SIA Merck Sharp & Dohme Latvija Tel: +371 67 364224 msd_lv@merck.com | United Kingdom (Northern Ireland) Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfoNI@msd.com |
Last revision date of this leaflet:
The detailed information on this medicine is available on the website of the European Medicines Agency:https://www.ema.europa.eu.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.